# A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months

> **NCT06049927** · PHASE3 · COMPLETED · sponsor: **Sinovac Biotech Co., Ltd** · enrollment: 3300 (actual)

## Conditions studied

- Seasonal Influenza

## Interventions

- **BIOLOGICAL:** Quadrivalent influenza vaccine(0.25ml)
- **BIOLOGICAL:** Quadrivalent influenza vaccine(0.5ml)
- **BIOLOGICAL:** Trivalent influenza vaccine(BV)
- **BIOLOGICAL:** Trivalent influenza vaccine(BY)

## Key facts

- **NCT ID:** NCT06049927
- **Lead sponsor:** Sinovac Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-16
- **Primary completion:** 2024-05-23
- **Final completion:** 2024-05-23
- **Target enrollment:** 3300 (ACTUAL)
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06049927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06049927, "A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT06049927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*